Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:JANXNASDAQ:TRMLNASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$30.76-4.8%$33.29$27.14▼$62.58$1.76B0.9684,071 shs355,436 shsJANXJanux Therapeutics$30.83-2.9%$36.33$28.92▼$71.71$1.82B3.23828,068 shs564,295 shsTRMLTourmaline Bio$17.12-2.8%$15.33$11.87▼$29.79$439.73M2.35274,364 shs483,541 shsTVTXTravere Therapeutics$21.01-1.3%$20.64$5.12▼$25.29$1.86B0.751.42 million shs975,544 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+3.23%+1.00%-8.25%-5.50%+8.13%JANXJanux Therapeutics+6.01%+0.73%-11.86%-43.46%-19.71%TRMLTourmaline Bio+2.68%-3.56%+44.23%-17.71%-28.62%TVTXTravere Therapeutics+3.70%+2.01%-3.14%+24.28%+170.18%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.3461 of 5 stars3.33.00.04.32.90.81.9JANXJanux Therapeutics3.5421 of 5 stars4.51.00.00.02.85.00.0TRMLTourmaline Bio1.1176 of 5 stars3.50.00.00.00.02.50.0TVTXTravere Therapeutics2.9616 of 5 stars4.52.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.5783.91% UpsideJANXJanux Therapeutics 3.08Buy$92.44199.85% UpsideTRMLTourmaline Bio 3.00Buy$45.20164.02% UpsideTVTXTravere Therapeutics 2.93Moderate Buy$30.6245.72% UpsideCurrent Analyst Ratings BreakdownLatest TRML, JANX, TVTX, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.003/6/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.002/28/2025JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $76.002/26/2025TVTXTravere TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $44.002/24/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$58.00 ➝ $58.002/24/2025TRMLTourmaline BioLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$58.002/24/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$31.00 ➝ $35.002/21/2025TVTXTravere TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M48.29N/AN/A$27.02 per share1.14JANXJanux Therapeutics$10.59M172.10N/AN/A$7.46 per share4.13TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/ATVTXTravere Therapeutics$233.18M8.00N/AN/A$2.67 per share7.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.342.71N/AN/A1,845.92%-2.51%-2.26%5/1/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.28N/AN/AN/A-463.91%-10.47%-9.86%5/6/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$2.87N/AN/AN/AN/A-20.97%-20.56%5/12/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$4.10N/AN/AN/A-137.90%-1,636.87%-55.95%5/5/2025 (Estimated)Latest TRML, JANX, TVTX, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/A2/20/2025Q4 2024AGIOAgios Pharmaceuticals-$1.69-$1.74-$0.05-$1.74$9.35 millionN/A2/20/2025Q4 2024TVTXTravere Therapeutics-$0.58-$0.73-$0.15-$0.73$72.38 million$74.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56JANXJanux TherapeuticsN/A38.8038.80TRMLTourmaline BioN/A40.3340.33TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AJANXJanux Therapeutics75.39%TRMLTourmaline Bio91.89%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%JANXJanux Therapeutics29.40%TRMLTourmaline Bio11.02%TVTXTravere Therapeutics3.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.30 million54.47 millionOptionableJANXJanux Therapeutics3059.11 million37.05 millionOptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableTVTXTravere Therapeutics46088.74 million75.12 millionOptionableTRML, JANX, TVTX, and AGIO HeadlinesRecent News About These CompaniesEmerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)March 24 at 7:08 AM | marketbeat.comSemanteon Capital Management LP Acquires 48,084 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)March 22 at 6:04 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Charles Schwab Investment Management Inc.March 22 at 3:15 AM | marketbeat.comTravere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGSMarch 17, 2025 | finanznachrichten.deTravere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGSMarch 17, 2025 | markets.businessinsider.comTravere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGSMarch 17, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Has $7.43 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)March 16, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 15, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 15, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Up 6.7% - Time to Buy?March 13, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 12, 2025 | globenewswire.comUS Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)March 12, 2025 | marketbeat.comTravere Therapeutics: Tricky Outlook Gives Me Pause For Thought - DowngradeMarch 7, 2025 | seekingalpha.comIeq Capital LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)February 28, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for TVTXFebruary 27, 2025 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockFebruary 26, 2025 | marketbeat.comWedbush Predicts Lower Earnings for Travere TherapeuticsFebruary 26, 2025 | marketbeat.comImpax Asset Management Group plc Takes $5.23 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)February 25, 2025 | marketbeat.comTravere Therapeutics to Participate at Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comTravere Therapeutics price target raised to $35 from $31 at CitiFebruary 24, 2025 | markets.businessinsider.comTravere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025February 23, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, JANX, TVTX, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$30.76 -1.55 (-4.80%) Closing price 04:00 PM EasternExtended Trading$30.67 -0.09 (-0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Janux Therapeutics NASDAQ:JANX$30.83 -0.91 (-2.87%) Closing price 04:00 PM EasternExtended Trading$30.84 +0.01 (+0.03%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Tourmaline Bio NASDAQ:TRML$17.12 -0.49 (-2.78%) Closing price 04:00 PM EasternExtended Trading$17.12 +0.00 (+0.03%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Travere Therapeutics NASDAQ:TVTX$21.01 -0.28 (-1.32%) Closing price 04:00 PM EasternExtended Trading$21.00 -0.01 (-0.02%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
